Commitment to R&D for AMR
Nine companies have committed to R&D for antimicrobial resistance (AMR), signing the Davos Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance.
- What: The Davos Declaration is a commitment from companies to contribute to a global response to the threat of antimicrobial resistance (AMR), including by investing in R&D that meets global public health needs.
- Objective: Through the delivery of a roadmap, the Davos Declaration aims to guide collaborative efforts between industry, governments and NGOs in the fight against AMR.
- Impact: The impact of the Declaration is global in nature.
- Scope: As of April 1st, 2016, signatories comprise 98 companies and 11 industry associations in 21 countries.
In January 2016, nine companies measured by the Access to Medicine Index 2016 (AstraZeneca, GSK, Johnson & Johnson, Merck & Co., Inc., Merck KGaA, Novartis, Pfizer, Roche and Sanofi) signed on to the Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance. The declaration formalised their commitment to respond to antimicrobial resistance (AMR), including through product R&D. As of April 1st, 2016, signatories comprise 98 companies and 11 industry associations in 21 countries.
Previously, some companies were involved in R&D relevant to AMR, for example through internal product development. In another example, DRIVE-AB, established in 2014, is a multi-sectoral initiative funded by the Innovative Medicines Initiative, which aims to identify how new economic models can be used to stimulate the development of novel antibiotics. Importantly, the Davos Declaration formalised commitments of many industry players and is the first example of an industry-led response to AMR that promotes open collaboration.
In September 2016, 8 of these companies (all except Merck KGaA) signed an Industry Roadmap for Progress on Combating Antimicrobial Resistance. This roadmap describes four key commitments the companies will deliver on, including improving access to new and existing antibiotics, diagnostics and vaccines, and collaborating with public partners to overcome innovation challenges in product R&D. These follow-up commitments are measurable, for example through the upcoming AMR Benchmark to be conducted by the Access to Medicine Foundation.